Danielle N. Yarde

Suggest Changes
Learn More
We conducted a Phase 1/2 study of bortezomib administered in combination with high-dose melphalan followed by tandem autologous transplants in patients with primary resistant multiple myeloma. Thirty(More)
  • 1